摘要
目的分析利培酮与奥氮平治疗脑血管病所致精神障碍的治疗效果。方法 100例脑血管病所致精神障碍患者按照就诊先后顺序编号,采用随机数字表法分为利培酮组与奥氮平组,各50例,利培酮组采用利培酮进行治疗,奥氮平组采用奥氮平进行治疗,比较两组治疗效果、阳性和阴性症状量表(PANSS)评分、日常生活能力量表(ADL)评分以及不良反应发生情况。结果治疗前及治疗后第2、4周,两组PANSS和ADL评分比较,差异均无统计学意义(P>0.05)。治疗后第2、4、8周,两组PANSS评分与治疗前比较,差异均有统计学意义(P<0.05);治疗后第4、8周,两组ADL评分与治疗前比较,差异均有统计学意义(P<0.05);治疗后第8周两组PANSS比较差异无统计学意义(P>0.05),但利培酮组的ADL评分优于奥氮平组,差异有统计学意义(P<0.05)。利培酮组治疗总有效率为92%,奥氮平组治疗总有效率为86%;两组治疗总有效率比较,差异无统计学意义(P>0.05)。两组嗜睡、锥体外系反应、肝功能异常、肾功能异常发生情况比较,差异均有统计学意义(P<0.05);两组体质量异常、心电图异常、其他不良反应发生情况比较,差异均无统计学意义(P>0.05);利培酮组总不良反应发生率为42%,低于奥氮平组的58%,但差异无统计学意义(P>0.05)。结论利培酮与奥氮平治疗脑血管病所致精神障碍均有良好效果,两组的治疗总有效率相当,且均能改善患者的日常生活质量,但两组均会不同程度地产生一些不良反应,需根据患者病情及身体情况有针对性地调整用药量,以促进患者康复。
Objective To analyze the efficacy of Risperidone and Olanzapine in the treatment of mental disorders caused by cerebrovascular disease. Methods A total of 100 patients with mental disorders caused by cerebrovascular disease were divided into Risperidone group and Olanzapine group according to the order of consultation and by the random number table method, 50 cases in each group. The Risperidone group was treated with Risperidone, and the Olanzapine group was treated with Olanzapine. The curative effect, positive and negative symptom scale （PANSS） score, activity of daily living scale （ADL） score and occurrence of adverse reactions between the two groups were compared. Results There were no significant differences in the PANSS and ADL scores between the two groups before treatment and 2 and 4 weeks after treatment （P〉0.05）. At the 2nd, 4th and 8th week after treatment, the PANSS scores of the two groups were significantly different from those before treatment, the differences were statistically significant （P〈0.05）. At the 4th and 8th week after treatment, the ADL scores of the two groups were significantly different from those before treatment, the differences were statistically significant （P〈0.05）. At 8th week after treatment, there were no significant differences in the scores of PANSS between the two groups （P〉0.05）, and the ADL score of Risperidone group was signficantly better than that of Olanzapine group, the difference was statistically signficant （P〈0.05）. The total effective rate of the Risperidone group was 92%, and that of the Olanzapine group was 86%, there was no significant difference between the two groups （P〉0.05）. There were significant differences in the occurrence of somnolence, extrapyramidal reaction, abnormal liver function and renal function between the two groups （P〈0.05）. There were no significant differences in the occurrence of body mass abnormality, electrocardiogram abnormality and other adverse reactions between the two groups （P〉0.05）. The total incidence rate of adverse reactions in the Risperidone group was 42%, which was significantly lower than 58% in the Olanzapine group, but the difference was not statistically significant （P〉0.05）. Conclusion Risperidone and Olanzapine in the treatment of mental disorders caused by cerebrovascular disease all have good effects, the total effective rates of both treatments are equal, they can improve the quality of daily life of patients, but both groups will produce some adverse reactions to different degrees, and targeted dosage adjustment should be made according to the patients’ condition and physical condition in order to promote the rehabilitation of patients.
作者
沈勇生
SHEN Yong-sheng(Zhangzhou Fukang Hospital,Zhangzhou 363000,China)
出处
《中国现代药物应用》
2018年第21期4-6,共3页
Chinese Journal of Modern Drug Application
关键词
利培酮
奥氮平
脑血管病
精神障碍
疗效分析
Risperidone
Olanzapine
Cerebrovascular disease
Mental disorder
Efficacy analysis
